Almac Diagnostics and Rosetta Biosoftware have announced that Almac Diagnostics (formerly ArraDx Ltd) licensed the Rosetta Resolver® system for use in the development of microarray-based approaches for diagnosing cancer and predicting therapeutic outcomes.
The Resolver system will also be used in the provision of comprehensive gene expression analysis services offered by Almac Diagnostics to academic, biotech and pharmaceutical customers.
"We are pleased to continue to expand our business by supporting cancer diagnostic research," said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware.
"The Resolver system provides a flexible platform to enable researchers to use microarray data in a large biological context, such as the development of disease-specific microarrays for diagnosing cancer."
"At Almac Diagnostics, we are dedicated to promoting discovery," said Professor Paul Harkin, CEO of Almac Diagnostics.
"Almac Diagnostics is pioneering a novel transcriptomics-based approach to develop tools, which will radically improve diagnosis and treatment of cancer."
"The Resolver system provides the comprehensive solution necessary for us to advance this type of research and realize more targeted and personalized approaches for cancer diagnosis and prognosis."
"Furthermore, our use of the Resolver system will allow all our service customers to benefit from state-of-the-art technology in gene expression data management, analysis and visualization."